Enlimomab (BIRR1/R6.5), another anti-human ICAM-1 antibody, was also tested in clinical trials to treat rheumatoid arthritis, prevent acute rejection of renal transplants and in acute stroke patients, and showed some clinical improvements for arthritis as well as stroke patients and importantly good tolerability [59, 60]. This evidence concerns the gene ICAM1 and stroke disorder.